Myeloid growth factors

Jeffrey Crawford, James Olen Armitage, Lodovico Balducci, Pamela Sue Becker, Douglas W. Blayney, Spero R. Cataland, Mark L. Heaney, Susan Hudock, Dwight D. Kloth, David J. Kuter, Gary H. Lyman, Brandon McMahon, Hope S. Rugo, Ayman A. Saad, Lee S. Schwartzberg, Sepideh Shayani, David P. Steensma, Mahsa Talbott, Saroj Vadhan-Raj, Peter Westervelt & 3 others Michael Westmoreland, Mary Dwyer, Maria Ho

Research output: Contribution to journalReview article

39 Citations (Scopus)

Abstract

Febrile neutropenia, a common side effect of myelosup-pressive chemotherapy in patients with cancer, can result in prolonged hospitalization and broad-spectrum antibiotic use, often prompting treatment delays or dose reductions of drug regimens. Prophylactic use of myeloid growth factors (mainly the colony-stimulating factors filgrastim and pegfilgrastim) in patients of heightened risk can reduce the severity and duration of febrile neutropenia. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Myeloid Growth Factors provide recommendations on the use of these agents mainly in the oncology setting based on clinical evidence and expert consensus. This version includes revisions surrounding the issue of timing of pegfilgrastim administration. It also includes new sections on tbo-filgrastim, a recently approved agent that is biologically similar to filgrastim, and the role of myeloid growth factors in the hematopoietic cell transplant setting.

Original languageEnglish (US)
Pages (from-to)1266-1290
Number of pages25
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume11
Issue number10
DOIs
StatePublished - Oct 1 2013

Fingerprint

Febrile Neutropenia
Intercellular Signaling Peptides and Proteins
Colony-Stimulating Factors
Practice Guidelines
Hospitalization
Guidelines
Anti-Bacterial Agents
Transplants
Drug Therapy
Pharmaceutical Preparations
Filgrastim
Neoplasms
pegfilgrastim
Therapeutics

ASJC Scopus subject areas

  • Oncology

Cite this

Crawford, J., Armitage, J. O., Balducci, L., Becker, P. S., Blayney, D. W., Cataland, S. R., ... Ho, M. (2013). Myeloid growth factors. JNCCN Journal of the National Comprehensive Cancer Network, 11(10), 1266-1290. https://doi.org/10.6004/jnccn.2013.0148

Myeloid growth factors. / Crawford, Jeffrey; Armitage, James Olen; Balducci, Lodovico; Becker, Pamela Sue; Blayney, Douglas W.; Cataland, Spero R.; Heaney, Mark L.; Hudock, Susan; Kloth, Dwight D.; Kuter, David J.; Lyman, Gary H.; McMahon, Brandon; Rugo, Hope S.; Saad, Ayman A.; Schwartzberg, Lee S.; Shayani, Sepideh; Steensma, David P.; Talbott, Mahsa; Vadhan-Raj, Saroj; Westervelt, Peter; Westmoreland, Michael; Dwyer, Mary; Ho, Maria.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 11, No. 10, 01.10.2013, p. 1266-1290.

Research output: Contribution to journalReview article

Crawford, J, Armitage, JO, Balducci, L, Becker, PS, Blayney, DW, Cataland, SR, Heaney, ML, Hudock, S, Kloth, DD, Kuter, DJ, Lyman, GH, McMahon, B, Rugo, HS, Saad, AA, Schwartzberg, LS, Shayani, S, Steensma, DP, Talbott, M, Vadhan-Raj, S, Westervelt, P, Westmoreland, M, Dwyer, M & Ho, M 2013, 'Myeloid growth factors', JNCCN Journal of the National Comprehensive Cancer Network, vol. 11, no. 10, pp. 1266-1290. https://doi.org/10.6004/jnccn.2013.0148
Crawford J, Armitage JO, Balducci L, Becker PS, Blayney DW, Cataland SR et al. Myeloid growth factors. JNCCN Journal of the National Comprehensive Cancer Network. 2013 Oct 1;11(10):1266-1290. https://doi.org/10.6004/jnccn.2013.0148
Crawford, Jeffrey ; Armitage, James Olen ; Balducci, Lodovico ; Becker, Pamela Sue ; Blayney, Douglas W. ; Cataland, Spero R. ; Heaney, Mark L. ; Hudock, Susan ; Kloth, Dwight D. ; Kuter, David J. ; Lyman, Gary H. ; McMahon, Brandon ; Rugo, Hope S. ; Saad, Ayman A. ; Schwartzberg, Lee S. ; Shayani, Sepideh ; Steensma, David P. ; Talbott, Mahsa ; Vadhan-Raj, Saroj ; Westervelt, Peter ; Westmoreland, Michael ; Dwyer, Mary ; Ho, Maria. / Myeloid growth factors. In: JNCCN Journal of the National Comprehensive Cancer Network. 2013 ; Vol. 11, No. 10. pp. 1266-1290.
@article{3b85e35cba2440cdb7cdd97576436b05,
title = "Myeloid growth factors",
abstract = "Febrile neutropenia, a common side effect of myelosup-pressive chemotherapy in patients with cancer, can result in prolonged hospitalization and broad-spectrum antibiotic use, often prompting treatment delays or dose reductions of drug regimens. Prophylactic use of myeloid growth factors (mainly the colony-stimulating factors filgrastim and pegfilgrastim) in patients of heightened risk can reduce the severity and duration of febrile neutropenia. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Myeloid Growth Factors provide recommendations on the use of these agents mainly in the oncology setting based on clinical evidence and expert consensus. This version includes revisions surrounding the issue of timing of pegfilgrastim administration. It also includes new sections on tbo-filgrastim, a recently approved agent that is biologically similar to filgrastim, and the role of myeloid growth factors in the hematopoietic cell transplant setting.",
author = "Jeffrey Crawford and Armitage, {James Olen} and Lodovico Balducci and Becker, {Pamela Sue} and Blayney, {Douglas W.} and Cataland, {Spero R.} and Heaney, {Mark L.} and Susan Hudock and Kloth, {Dwight D.} and Kuter, {David J.} and Lyman, {Gary H.} and Brandon McMahon and Rugo, {Hope S.} and Saad, {Ayman A.} and Schwartzberg, {Lee S.} and Sepideh Shayani and Steensma, {David P.} and Mahsa Talbott and Saroj Vadhan-Raj and Peter Westervelt and Michael Westmoreland and Mary Dwyer and Maria Ho",
year = "2013",
month = "10",
day = "1",
doi = "10.6004/jnccn.2013.0148",
language = "English (US)",
volume = "11",
pages = "1266--1290",
journal = "JNCCN Journal of the National Comprehensive Cancer Network",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "10",

}

TY - JOUR

T1 - Myeloid growth factors

AU - Crawford, Jeffrey

AU - Armitage, James Olen

AU - Balducci, Lodovico

AU - Becker, Pamela Sue

AU - Blayney, Douglas W.

AU - Cataland, Spero R.

AU - Heaney, Mark L.

AU - Hudock, Susan

AU - Kloth, Dwight D.

AU - Kuter, David J.

AU - Lyman, Gary H.

AU - McMahon, Brandon

AU - Rugo, Hope S.

AU - Saad, Ayman A.

AU - Schwartzberg, Lee S.

AU - Shayani, Sepideh

AU - Steensma, David P.

AU - Talbott, Mahsa

AU - Vadhan-Raj, Saroj

AU - Westervelt, Peter

AU - Westmoreland, Michael

AU - Dwyer, Mary

AU - Ho, Maria

PY - 2013/10/1

Y1 - 2013/10/1

N2 - Febrile neutropenia, a common side effect of myelosup-pressive chemotherapy in patients with cancer, can result in prolonged hospitalization and broad-spectrum antibiotic use, often prompting treatment delays or dose reductions of drug regimens. Prophylactic use of myeloid growth factors (mainly the colony-stimulating factors filgrastim and pegfilgrastim) in patients of heightened risk can reduce the severity and duration of febrile neutropenia. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Myeloid Growth Factors provide recommendations on the use of these agents mainly in the oncology setting based on clinical evidence and expert consensus. This version includes revisions surrounding the issue of timing of pegfilgrastim administration. It also includes new sections on tbo-filgrastim, a recently approved agent that is biologically similar to filgrastim, and the role of myeloid growth factors in the hematopoietic cell transplant setting.

AB - Febrile neutropenia, a common side effect of myelosup-pressive chemotherapy in patients with cancer, can result in prolonged hospitalization and broad-spectrum antibiotic use, often prompting treatment delays or dose reductions of drug regimens. Prophylactic use of myeloid growth factors (mainly the colony-stimulating factors filgrastim and pegfilgrastim) in patients of heightened risk can reduce the severity and duration of febrile neutropenia. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Myeloid Growth Factors provide recommendations on the use of these agents mainly in the oncology setting based on clinical evidence and expert consensus. This version includes revisions surrounding the issue of timing of pegfilgrastim administration. It also includes new sections on tbo-filgrastim, a recently approved agent that is biologically similar to filgrastim, and the role of myeloid growth factors in the hematopoietic cell transplant setting.

UR - http://www.scopus.com/inward/record.url?scp=84887251759&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887251759&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2013.0148

DO - 10.6004/jnccn.2013.0148

M3 - Review article

VL - 11

SP - 1266

EP - 1290

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

SN - 1540-1405

IS - 10

ER -